MRK
Merck & Co., Inc. is a global pharmaceutical and animal health company that discovers, develops, and manufactures prescription medicines, biologic therapies, and vaccines for human diseases as well as veterinary products for livestock and companion animals. Merck's human pharmaceutical portfolio includes both therapeutic treatments and preventive vaccines across multiple disease areas, with its leading product being Keytruda (an immunotherapy), along with vaccines like Gardasil and treatments for diabetes and other conditions. The company operates two segments—Pharmaceutical (human health medicines and vaccines) and Animal Health (veterinary pharmaceuticals, vaccines, and health management solutions)—and sells primarily to wholesalers, retailers, hospitals, physicians, and government agencies.
Pipeline
Anti-PD-L1 monoclonal antibody (Tecentriq) that blocks PD-L1, restoring T-cell anti-tumor activity. Approved in NSCLC, SCLC, urothelial, and hepatocellular carcinoma.
Oral selective HIF-2α inhibitor (Welireg) that blocks the transcription factor driving VHL-mutant tumors. Approved in von Hippel-Lindau-associated renal cell carcinoma and advanced clear cell RCC.
Oral multi-kinase inhibitor (Cabometyx) targeting VEGFR2, MET, and AXL. Approved in renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.
Oral reversible non-covalent BTK inhibitor (MK-1026, Merck) active against C481-mutant BTK that resists covalent inhibitors. Phase 3 in CLL/SLL.